These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

462 related articles for article (PubMed ID: 1453209)

  • 21. Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma.
    Prince HM; Crump M; Imrie K; Stewart AK; Girouard C; Brandwein JM; Carstairs K; Pantalony D; Scott G; Sutcliffe S; Sutton DM; Tsang R; Keating A
    Ann Oncol; 1996 Dec; 7(10):1043-9. PubMed ID: 9037363
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial.
    Longo DL; DeVita VT; Duffey PL; Wesley MN; Ihde DC; Hubbard SM; Gilliom M; Jaffe ES; Cossman J; Fisher RI
    J Clin Oncol; 1991 Jan; 9(1):25-38. PubMed ID: 1702144
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prolonged disease-free survival after ablative chemoradiotherapy and autologous bone marrow transplantation in adult malignant lymphoma.
    Da WM; Zhong JT; Liu Y; Huang YS; Bai H; Wu XX; Ou YX; Wang CB; Xu SF
    Chin Med J (Engl); 1993 Apr; 106(4):277-81. PubMed ID: 8325155
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of patients with relapsed and resistant non-Hodgkin's lymphoma using total body irradiation, etoposide, and cyclophosphamide and autologous bone marrow transplantation.
    Gulati S; Yahalom J; Acaba L; Reich L; Motzer R; Crown J; Toia M; Igarashi T; Lemoli R; Hanninen E
    J Clin Oncol; 1992 Jun; 10(6):936-41. PubMed ID: 1588372
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adult lymphoblastic lymphoma in Taiwan: an analysis of treatment results of 26 patients.
    Chen YC; Ho CL; Kao WY; Hwang JM; Sheu LF; Chao TY
    Ann Hematol; 2001 Nov; 80(11):647-52. PubMed ID: 11757723
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Parma international protocol: pilot study of DHAP followed by involved-field radiotherapy and BEAC with autologous bone marrow transplantation.
    Philip T; Chauvin F; Armitage J; Bron D; Hagenbeek A; Biron P; Spitzer G; Velasquez W; Weisenburger DD; Fernandez-Ranada J
    Blood; 1991 Apr; 77(7):1587-92. PubMed ID: 2009374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PARMA international protocol: pilot study on 50 patients and preliminary analysis of the ongoing randomized study (62 patients).
    Philip T; Chauvin F; Bron D; Guglielmi C; Hagenbeek A; Coiffier B; Gisselbrecht C; Kluin Nelemans JC; Somers R; Misset JC
    Ann Oncol; 1991 Jan; 2 Suppl 1():57-64. PubMed ID: 2043500
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The optimal timing of autologous bone marrow transplantation in Hodgkin's disease patients after a chemotherapy relapse.
    Desch CE; Lasala MR; Smith TJ; Hillner BE
    J Clin Oncol; 1992 Feb; 10(2):200-9. PubMed ID: 1531067
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin's lymphoma: a literature review.
    Haw R; Sawka CA; Franssen E; Berinstein NL
    J Clin Oncol; 1994 May; 12(5):1074-84. PubMed ID: 8164032
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma.
    Mills W; Chopra R; McMillan A; Pearce R; Linch DC; Goldstone AH
    J Clin Oncol; 1995 Mar; 13(3):588-95. PubMed ID: 7884420
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accelerated hyperfractionated total-lymphoid irradiation, high-dose chemotherapy, and autologous bone marrow transplantation for refractory and relapsing patients with Hodgkin's disease.
    Yahalom J; Gulati SC; Toia M; Maslak P; McCarron EG; O'Brien JP; Portlock CS; Straus DJ; Phillips J; Fuks Z
    J Clin Oncol; 1993 Jun; 11(6):1062-70. PubMed ID: 8501492
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The role of intensive therapy and autologous blood and marrow transplantation for chemotherapy-sensitive relapsed and primary refractory non-Hodgkin's lymphoma: identification of major prognostic groups.
    Prince HM; Imrie K; Crump M; Stewart AK; Girouard C; Colwill R; Brandwein J; Tsang RW; Scott JG; Sutton DM; Pantalony D; Carstairs K; Sutcliffe SB; Keating A
    Br J Haematol; 1996 Mar; 92(4):880-9. PubMed ID: 8616081
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term follow-up of ProMACE-CytaBOM in non-Hodgkin's lymphomas.
    Fisher RI; Longo DL; DeVita VT; Hubbard SM; Miller TP; Young RC
    Ann Oncol; 1991 Jan; 2 Suppl 1():33-5. PubMed ID: 1710487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Autologous stem-cell transplantation for poor-risk and relapsed intermediate- and high-grade non-Hodgkin's lymphoma.
    Nademanee A; Molina A; Dagis A; Snyder DS; O'Donnell MR; Parker P; Stein A; Smith E; Planas I; Kashyap A; Spielberger R; Fung H; Krishnan A; Bhatia R; Wong KK; Somlo G; Margolin K; Chow W; Sniecinski I; Vora N; Slovak M; Niland JC; Forman SJ
    Clin Lymphoma; 2000 Jun; 1(1):46-54. PubMed ID: 11707813
    [TBL] [Abstract][Full Text] [Related]  

  • 35. High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin's disease: results in 85 patients with analysis of prognostic factors.
    Nademanee A; O'Donnell MR; Snyder DS; Schmidt GM; Parker PM; Stein AS; Smith EP; Molina A; Stepan DE; Somlo G
    Blood; 1995 Mar; 85(5):1381-90. PubMed ID: 7858268
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of high-dose combination chemotherapy and autologous bone marrow transplantation for patients with non-Hodgkin's lymphomas who are still responsive to conventional-dose therapy.
    Gribben JG; Goldstone AH; Linch DC; Taghipour G; McMillan AK; Souhami RL; Earl H; Richards JD
    J Clin Oncol; 1989 Nov; 7(11):1621-9. PubMed ID: 2809678
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Favorable outcome of patients with relapsed or refractory Hodgkin's disease treated with high-dose chemotherapy and stem cell rescue at the time of maximal response to conventional salvage therapy (Dex-BEAM).
    Josting A; Kàtay I; Rueffer U; Winter S; Tesch H; Engert A; Diehl V; Wickramanayake PD
    Ann Oncol; 1998 Mar; 9(3):289-95. PubMed ID: 9602263
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive chemotherapy with cyclophosphamide, carmustine, and etoposide followed by autologous bone marrow transplantation for relapsed Hodgkin's disease.
    Reece DE; Barnett MJ; Connors JM; Fairey RN; Fay JW; Greer JP; Herzig GP; Herzig RH; Klingemann HG; LeMaistre CF
    J Clin Oncol; 1991 Oct; 9(10):1871-9. PubMed ID: 1919637
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
    Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
    Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.